ACT Capital Management’s Bionano Genomics BNGO Stock Holding History

ACT Capital Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-58	Closed	-$257K	–	113
2021 Q2	$257K	Buy	+58	New	+$229K	0.13%	82

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACT Capital Management's BNGO Position: Q3 2021 in Review

ACT Capital Management sold out of Bionano Genomics (BNGO) in Q3 2021, closing a stake of 58 shares — an estimated $257K sold.

ACT Capital Management first reported a position in BNGO in Q2 2021 and held it in 1 quarter. The position peaked at $257K in Q2 2021. 147 funds tracked by Wall St. Rank hold BNGO as of Q3 2021.

ACT Capital Management reported no remaining Bionano Genomics position as of Q3 2021 after selling out during the quarter.
ACT Capital Management sold 58 Bionano Genomics shares in Q3 2021, an estimated $257K.
ACT Capital Management first reported a position in Bionano Genomics in Q2 2021 and held it in 1 quarter.
ACT Capital Management's Bionano Genomics position peaked at $257K in Q2 2021.
147 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.